{"schema_version":"1","generated_at":"2026-11-04T06:26:49.471Z","data_as_of":null,"url":"https://www.findmykol.com/kol/noffar-bar","json_url":"https://www.findmykol.com/kol/noffar-bar/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"noffar-bar","name":"Noffar Bar","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Yale Cancer Center","institution_url":"https://www.findmykol.com/institution/yale-school-of-medicine","city":"New Haven","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1215179106","orcid":"0000-0002-8383-1867","openalex":"A5108695850"},"summary":"Noffar Bar is an Oncology physician affiliated with Yale Cancer Center. OpenAlex indexes 94 publications with 2,482 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":94,"cited_by_count":2482,"h_index":15,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06993675","title":"Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Noffar Bar","source_url":"https://clinicaltrials.gov/study/NCT06993675","trial_url":"https://www.findmykol.com/trial/NCT06993675"},{"nct":"NCT02784483","title":"Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Yale University","source_url":"https://clinicaltrials.gov/study/NCT02784483","trial_url":"https://www.findmykol.com/trial/NCT02784483"}],"source":"trials"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":24,"shown":3,"withheld":21,"rows":[{"payer":"Bristol Myers Squibb","program_year":2025,"amount_usd":1115473.35,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215179106"},{"payer":"Janssen","program_year":2025,"amount_usd":964148.32,"payment_count":79,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215179106"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":2134.68,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215179106"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1215179106","source":"payments"},"prescribing":{"data_year":2024,"areas_total":7,"areas_shown":3,"areas":[{"area":"Dermatology","share_pct":39,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":39,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":27}]},{"area":"Blood & clotting","share_pct":16.6,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":16.6,"drugs":[{"name":"Eliquis","share_pct":100}],"max_beneficiaries":null}]},{"area":"Sensory organs","share_pct":11.8,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":11.8,"drugs":[{"name":"Dexamethasone","share_pct":100}],"max_beneficiaries":13}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":60.6,"facility_pct":39.4},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study","year":2026,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-025-02841-x","status":"verified"},{"title":"Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series","year":2026,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-026-01473-3","status":"verified"},{"title":"Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison","year":2026,"journal":"Advances in Therapy","source_url":"https://doi.org/10.1007/s12325-025-03479-y","status":"verified"},{"title":"Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial","year":2025,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.01.047","status":"verified"},{"title":"Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2024-201533","status":"verified"}],"source":"works"},"contact":{"address_1":"20 YORK ST # T-209","address_2":"YALE-NEW HAVEN HOSPITAL","city":"New Haven","state":"CT","zip":"065103220","phone":"203-688-2259","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1215179106","source":"identity"},"similar":[{"name":"Ian Krop","slug":"ian-krop","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ian-krop","json_url":"https://www.findmykol.com/kol/ian-krop/profile.json"},{"name":"Harriet Kluger","slug":"harriet-kluger","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/harriet-kluger","json_url":"https://www.findmykol.com/kol/harriet-kluger/profile.json"},{"name":"Stephanie Halene","slug":"stephanie-halene","institution":"Yale Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/stephanie-halene","json_url":"https://www.findmykol.com/kol/stephanie-halene/profile.json"},{"name":"John Kunstman","slug":"john-kunstman","institution":"Yale Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/john-kunstman","json_url":"https://www.findmykol.com/kol/john-kunstman/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":21,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2016-08-18","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}